Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP081
MIFTS: 49

Hypolipoproteinemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Metabolic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypolipoproteinemia

About this section

MalaCards integrated aliases for Hypolipoproteinemia:

Name: Hypolipoproteinemia 12 73 20 15
Lipoprotein Deficiencies 12 54
Lipoprotein Disorder 54 70
Hypolipoproteinaemia 12
Hypolipoproteinemias 44
Lipoprotein 17

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1387
ICD9CM 34 272.5
MeSH 44 D007009
SNOMED-CT 67 363140000
ICD10 32 E78.6
UMLS 70 C0020623 C0596848
Sources

Summaries for Hypolipoproteinemia

About this section
GARD : 20 Hypolipoproteinemia refers to unusually low levels of fats (lipids) in the blood. Low lipid levels may be caused by rare genetic conditions, or be a sign of another disorder such as overactive thyroid, anemia, undernutrition, cancer, chronic infection, or impaired absorption of foods from the digestive tract. Associated genetic disorders includes abetalipoproteinemia, familial hypobetalipoproteinemia, and chylomicron retention disease. Signs and symptoms in the the genetic or familial form of hypolipoproteinemia vary. In hypobetalipoproteinemia the low density lipoprotein (LDL) cholesterol levels are very low, yet people with this syndrome typically have no symptoms nor require treatment. Other forms result in absent or near absent LDL levels and can cause serious symptoms in infancy and early childhood. Treatment for hypoproteinemia varies depending on the underlying cause and signs and symptoms present in each individual.

MalaCards based summary : Hypolipoproteinemia, also known as lipoprotein deficiencies, is related to hypoalphalipoproteinemia, primary, 1 and lipoprotein glomerulopathy. An important gene associated with Hypolipoproteinemia is ABCA1 (ATP Binding Cassette Subfamily A Member 1), and among its related pathways/superpathways are Metabolism and Metabolism of water-soluble vitamins and cofactors. The drugs Metformin and Exenatide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and bone, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Wikipedia : 73 Hypolipoproteinemia, hypolipidemia, or hypolipidaemia (British English) is a form of dyslipidemia that... more...

Sources

Related Diseases for Hypolipoproteinemia

About this section

Diseases related to Hypolipoproteinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1204)
# Related Disease Score Top Affiliating Genes
1 hypoalphalipoproteinemia, primary, 1 32.7 APOA1 ABCA1
2 lipoprotein glomerulopathy 32.5 LPA LCAT APOE APOB APOA2
3 hypoalphalipoproteinemia, primary, 2 32.3 APOA1 ABCA1
4 hepatic lipase deficiency 32.2 LPL APOE APOA1
5 familial lipoprotein lipase deficiency 32.1 LPL APOE APOC3 APOC2 APOB APOA1
6 hypercholesterolemia, familial, 2 32.0 APOE APOB
7 fish-eye disease 31.9 LCAT APOA2 APOA1
8 apolipoprotein c-iii deficiency 31.9 LPL APOC3
9 apolipoprotein c-ii deficiency 31.9 LPL APOC2
10 abdominal obesity-metabolic syndrome 1 31.8 MIR33A LPL APOB APOA1
11 hypoalphalipoproteinemia 31.8 LCAT APOA2 APOA1 ABCA1
12 arteries, anomalies of 31.7 MIR33A APOE APOB APOA1
13 chylomicron retention disease 31.6 SAR1B MTTP APOB APOA1
14 stroke, ischemic 31.5 LPA APOE APOB ABCA1
15 niemann-pick disease, type c1 31.4 SCARB1 ABCG5 ABCG1 ABCA1
16 lecithin:cholesterol acyltransferase deficiency 31.3 LPL LPA LCAT CETP APOE APOB
17 hyperlipoproteinemia, type v 31.3 LPL APOE APOC3 APOC2 APOB APOA1
18 hyperlipoproteinemia, type iii 31.3 LPL LPA CETP APOE APOC2 APOB
19 hypercholesterolemia, familial, 1 31.2 PCSK9 LPL LPA LCAT CETP APOE
20 hypertriglyceridemia, familial 31.2 LPL CETP APOE APOC3 APOC2 APOB
21 intermediate coronary syndrome 31.2 PCSK9 APOB APOA1
22 arteriosclerosis 31.1 LPA APOE APOB APOA1
23 hypobetalipoproteinemia, familial, 2 31.0 PLTP PCSK9 APOC3 APOB ANGPTL3
24 homozygous familial hypercholesterolemia 30.9 PCSK9 APOE APOB APOA2 APOA1 ABCG5
25 hyperalphalipoproteinemia 1 30.9 SCARB1 PLTP LPL LCAT CETP APOC3
26 cerebrovascular disease 30.8 LPL LPA APOE APOB APOA1 ABCA1
27 lipoprotein quantitative trait locus 30.8 SCARB1 PLTP LPL LPA LCAT CETP
28 aortic valve disease 2 30.8 PCSK9 LPA APOB
29 uremia 30.8 LPL LCAT APOC3
30 hyperlipoproteinemia, type i 30.7 PCSK9 MTTP LPL LPA LCAT CETP
31 amyloidosis 30.6 LPA APOE APOA2 APOA1
32 hypothyroidism 30.6 LPA CETP APOB APOA1
33 peripheral artery disease 30.6 PCSK9 LPA APOE APOB APOA1
34 nephrotic syndrome 30.6 LPL LPA LCAT CETP APOE APOB
35 xanthomatosis 30.6 LPL LPA APOE APOB ABCA1
36 chronic kidney disease 30.5 LPL LPA LCAT CETP APOE APOB
37 peripheral vascular disease 30.5 PLTP LPA LCAT CETP APOB APOA2
38 coronary stenosis 30.5 SCARB1 PCSK9 LPL CETP APOE APOB
39 defective apolipoprotein b-100 30.4 PCSK9 LCAT APOE APOB
40 familial lcat deficiency 30.4 LCAT APOE APOA2 APOA1
41 coronary heart disease 1 30.4 PCSK9 MTTP LPL LPA LCAT CETP
42 cerebral atherosclerosis 30.4 APOE APOB APOA1
43 abetalipoproteinemia 30.4 SAR1B PCSK9 MTTP LPL LCAT CETP
44 cholelithiasis 30.3 SCARB1 APOE ABCG5
45 hypobetalipoproteinemia, familial, 1 30.3 SAR1B PCSK9 MTTP LCAT APOE APOC3
46 amyloidosis aa 30.3 LPA LCAT APOA1
47 carotid artery disease 30.2 LPA APOE APOB APOA2 APOA1
48 kidney disease 30.2 LPA LCAT CETP APOE APOC3 APOB
49 apo a-i deficiency 30.2 LCAT APOA1
50 silent myocardial infarction 30.2 APOB APOA1

Graphical network of the top 20 diseases related to Hypolipoproteinemia:



Diseases related to Hypolipoproteinemia
Sources

Symptoms & Phenotypes for Hypolipoproteinemia

About this section

GenomeRNAi Phenotypes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 ABCA1
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Hypolipoproteinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.86 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
2 liver/biliary system MP:0005370 9.4 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOB
Sources

Drugs & Therapeutics for Hypolipoproteinemia

About this section

Drugs for Hypolipoproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Lixisenatide Approved Phase 4 320367-13-3
5
Linagliptin Approved Phase 4 668270-12-0 10096344
6
Azithromycin Approved Phase 4 83905-01-5 447043 55185
7
Fenofibrate Approved Phase 4 49562-28-9 3339
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9 Orange Approved Phase 4
10
Probucol Approved, Investigational Phase 4 23288-49-5 4912
11
Testosterone Approved, Investigational Phase 4 58-22-0 6013
12
Methyltestosterone Approved Phase 4 58-18-4 6010
13
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
14
Testosterone enanthate Approved Phase 4 315-37-7 9416
15
Nevirapine Approved Phase 4 129618-40-2 4463
16
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
17
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
tannic acid Approved Phase 4 1401-55-4
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Ezetimibe Approved Phase 4 163222-33-1 150311
24
Glimepiride Approved Phase 4 93479-97-1 3476
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
27
Anagliptin Investigational Phase 4 739366-20-2
28 Anti-Bacterial Agents Phase 4
29 Calcium, Dietary Phase 4
30 Antiviral Agents Phase 4
31 Anti-Retroviral Agents Phase 4
32 Anti-HIV Agents Phase 4
33 Anti-Infective Agents Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Phytosterol Phase 4
36 Glycoside Hydrolase Inhibitors Phase 4
37 Cardiac Glycosides Phase 4
38 Colesevelam Hydrochloride Phase 4
39 Anabolic Agents Phase 4
40 Testosterone 17 beta-cypionate Phase 4
41 Androgens Phase 4
42 Reverse Transcriptase Inhibitors Phase 4
43 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
44 Rosuvastatin Calcium Phase 4 147098-20-2
45 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
46 Sodium-Glucose Transporter 2 Inhibitors Phase 4
47 Anticholesteremic Agents Phase 4
48 Antimetabolites Phase 4
49 Lipid Regulating Agents Phase 4
50 Hypolipidemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 354)
# Name Status NCT ID Phase Drugs
1 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
2 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
3 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects Unknown status NCT01301794 Phase 4
6 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
7 Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis Unknown status NCT03045198 Phase 4 Azithromycin
8 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
9 Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function Completed NCT00298909 Phase 4 niaspan (extended-release niacin);niacin
10 Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration. Completed NCT01321034 Phase 4 Niacin/Laropiprant
11 Effect of Tredaptive on Serum Lipoproteins, Lipoproteins Metabolism, Oxidative Stress and HDL Antioxidant Function Completed NCT01054508 Phase 4 nicotinic acid/laropiprant
12 Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol Completed NCT01122355 Phase 4 lipid modification
13 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
14 Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial Completed NCT02330406 Phase 4 Anagliptin;Sitagliptin
15 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood Completed NCT02839902 Phase 4 TAK-085
16 Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy. Completed NCT00249938 Phase 4 Minute Maid Heart Wise orange juice;Welchol
17 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
18 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
19 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
20 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
21 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
22 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
23 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
24 A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study) Completed NCT00645151 Phase 4 Atorvastatin;Atorvastatin;Atorvastatin
25 The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes Completed NCT01384058 Phase 4 ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20
26 Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
27 THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA Completed NCT00932620 Phase 4 SIMVASTATIN 40 mg;SIMVASTATIN/EZETIMIBE 10/10 mg
28 Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes Completed NCT02185963 Phase 4 Rosuvastatin
29 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
30 12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients Completed NCT00747149 Phase 4 Rosuvastatin
31 Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111434 Phase 4 Testosterone
32 SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers Completed NCT00194402 Phase 4 Slo-Niacin, atorvastatin
33 An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets Completed NCT00144261 Phase 4 nevirapine
34 Influence of Glitazones on the Vasodilatory Effect of HDL Lipoproteins and on Phospholipase A2 Completed NCT00953498 Phase 4 pioglitazone;rosiglitazone
35 Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial Recruiting NCT02579499 Phase 4 fixed high potent statin therapy;targeted LDL-C goal statin
36 Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes Recruiting NCT03269058 Phase 4 Dapagliflozin;Placebos
37 Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia Terminated NCT01239992 Phase 4 Niacin/ Laropiprant
38 A Pilot Study Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia in Clinical Routine Terminated NCT03559309 Phase 4
39 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes Terminated NCT00651014 Phase 4 Ezetimibe;Placebo
40 Effect of Sitagliptin on Postprandial Lipoprotein Metabolism Terminated NCT00939939 Phase 4 sitagliptin;glimepiride
41 An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia Withdrawn NCT02069106 Phase 4
42 Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters Withdrawn NCT01180764 Phase 4 Lovaza (Omega-3 acid ethyl esters);Placebo
43 A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X Unknown status NCT01109498 Phase 2, Phase 3 Mycophenolate mofetil;cyclosporine
44 Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study) Unknown status NCT00633698 Phase 3 Nicotinic acid (niacin);Placebo
45 Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) Unknown status NCT01286909 Phase 3
46 Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism Unknown status NCT01572259 Phase 3 Growth Hormone
47 Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patients With Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial Completed NCT03402204 Phase 3 Simvastatin 10 mg;Simvastatin 40 mg
48 An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects Completed NCT00891306 Phase 2, Phase 3 mycophenolate mofetil;cyclosporine;methylprednisolone
49 Long-Term, Open-Label, Safety and Tolerability Study of Ezetimibe (SCH 58235) in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin Completed NCT03882996 Phase 3 Ezetimibe;Atorvastatin
50 A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia Completed NCT00101439 Phase 3 ezetimibe;Comparator: placebo

Search NIH Clinical Center for Hypolipoproteinemia

Cochrane evidence based reviews: hypolipoproteinemias

Sources

Genetic Tests for Hypolipoproteinemia

About this section
Sources

Anatomical Context for Hypolipoproteinemia

About this section

MalaCards organs/tissues related to Hypolipoproteinemia:

40
Endothelial, Liver, Bone, Whole Blood, Heart
Sources

Publications for Hypolipoproteinemia

About this section

Articles related to Hypolipoproteinemia:

(show top 50) (show all 107)
# Title Authors PMID Year
1
A Population-Based Study on the Association between Periodontal Disease and Major Lifestyle-Related Comorbidities in South Korea: An Elderly Cohort Study from 2002-2015. 61
33138320 2020
2
Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. 61
30150141 2018
3
A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy). 61
30270073 2018
4
Simplified Canadian Definition for Familial Hypercholesterolemia. 61
30093300 2018
5
Severe xanthomatosis in heterozygous familial hypercholesterolemia. 61
29778561 2018
6
Association Between Blood Lipid Profiles and Atrial Fibrillation: A Case-Control Study. 61
29885277 2018
7
Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia. 61
24987866 2014
8
Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital. 61
25164551 2014
9
[Study on medical pattern of traditional Chinese medicine and western medicine diagnosis and treatment of hypertension patients in 30 034 cases in real world]. 61
25532374 2014
10
Emerging therapeutic agents to lower lipoprotein (a) levels. 61
23041907 2012
11
Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. 61
21955034 2012
12
[A comparative study of the efficacy and safety Zhibitai and atorvastatin]. 61
20646412 2010
13
New mutations in APOB100 involved in familial hypobetalipoproteinemia. 61
21122650 2010
14
[Primary bilateral lipid keratopathy]. 61
19466688 2009
15
[Obesity and insulin resistance among adolescents from Chiapas]. 61
19593490 2009
16
Hypolipoproteinemia and hyperinflammatory cytokines in serum of severe and moderate traumatic brain injury (TBI) patients. 61
17993453 2007
17
[Drug-induced hypolipoproteinemia]. 61
17824104 2007
18
Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. 61
16720894 2006
19
Tangier disease four decades of research: a reflection of the importance of HDL. 61
16611066 2006
20
Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm. 54
15719845 2005
21
[Hypolipoproteinemia and secondary role of atherosclerosis in the development of ischemic heart disease in patients with polycythemia vera]. 61
15699934 2005
22
Characteristics of lipids imbalance in patients with tick-borne encephalitis. 61
15560094 2004
23
Expression pattern and raft association of NIPSNAP3 and NIPSNAP4, highly homologous proteins encoded by genes in close proximity to the ATP-binding cassette transporter A1. 54
15177564 2004
24
Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. 54
15019541 2004
25
ATP-binding cassette (ABC) transporters in human metabolism and diseases. 54
15209530 2004
26
A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. 61
14709355 2004
27
Expression, regulation, and activity of ABCA1 in human cell lines. 54
12706378 2003
28
A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. 54
12535745 2003
29
Differentiating hyperlipidaemia associated with antiretroviral therapy. 54
12545078 2003
30
[Familial hypolipoproteinemia with liver steatosis]. 61
12239658 2002
31
ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. 61
11896206 2002
32
Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? 54
11861429 2002
33
Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. 54
11785958 2002
34
Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. 54
11476961 2001
35
High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (ABCA1) gene. 54
11558901 2001
36
Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease - the small G protein may play a role in cholesterol efflux. 61
11078892 2000
37
A critical evaluation of the putative role of C3adesArg (ASP) in lipid metabolism and hyperapobetalipoproteinemia. 61
10698341 1999
38
Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C]. 61
10487495 1999
39
Gene therapy for dyslipidemia: clinical prospects. 54
11122693 1999
40
Cholesterol paradox in patients with paroxysmal atrial fibrillation. 61
10640793 1999
41
Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. 61
9888879 1999
42
Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. 61
9812922 1998
43
[New approach from lipoprotein disorders to atherosclerosis]. 61
9721537 1998
44
Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. 61
9537421 1998
45
A competitive reverse transcription-PCR to study apolipoprotein epsilon gene expression. 61
9554488 1998
46
Lipoprotein disorder in brain infarction and hemorrhage. 61
9594362 1998
47
Etiologic heterogeneity of hyperapobetalipoproteinemia (hyperapoB). Results from segregation analysis in families with premature coronary artery disease. 61
9409249 1997
48
Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels. 61
9261642 1997
49
Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. 54
9185775 1997
50
Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. 61
9199276 1997
Sources

Variations for Hypolipoproteinemia

About this section
Sources

Expression for Hypolipoproteinemia

About this section
Search GEO for disease gene expression data for Hypolipoproteinemia.
Sources

Pathways for Hypolipoproteinemia

About this section

Pathways related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Metabolism 65
Show member pathways
 13.79 SCARB1 SAR1B PLTP PCSK9 MTTP LPL
2
Metabolism of water-soluble vitamins and cofactors 65
Show member pathways
 12.61 LPL APOE APOC3 APOC2 APOB APOA2
3
Folate Metabolism 1
Show member pathways
 12.24 SCARB1 APOE APOB APOA1 ABCA1
4
Metabolism of fat-soluble vitamins 65
Show member pathways
 12.2 LPL APOE APOC3 APOC2 APOB APOA2
5
Lipoprotein metabolism 65
Show member pathways
 12.14 SCARB1 SAR1B PLTP PCSK9 MTTP LPL
6
Statin Pathway 1
Show member pathways
 11.98 SCARB1 PLTP PCSK9 MTTP MIR33A LPL
7
Binding and Uptake of Ligands by Scavenger Receptors 65
Show member pathways
 11.85 SCARB1 APOE APOB APOA1
8
PPAR signaling pathway 36
11.68 PLTP LPL APOC3 APOA2 APOA1
9
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.66 SCARB1 SAR1B MIR33A LPL
10
Fat digestion and absorption 36
Show member pathways
 11.4 SCARB1 MTTP APOB APOA1 ABCG5 ABCA1
11
Vitamin A and Carotenoid Metabolism 1
11.37 SCARB1 LPL ABCG5
12
Nuclear Receptors in Lipid Metabolism and Toxicity 1
11.32 MIR33A ABCG5 ABCG1 ABCA1
13
PPAR Alpha Pathway 1
11.15 PLTP APOC3 APOA2 APOA1
14
Vitamin digestion and absorption 36
11.08 SCARB1 APOB APOA1
15
Cholesterol and Sphingolipids transport / Recycling to plasma membrane in lung (normal and CF) 23
10.95 APOA2 APOA1 ABCG1 ABCA1
16
SREBF and miR33 in cholesterol and lipid homeostasis 1
10.84 MIR33A ABCA1
Sources

GO Terms for Hypolipoproteinemia

About this section

Cellular components related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.25 PLTP PCSK9 LPL LPA LCAT CETP
2 extracellular space GO:0005615 10.2 PLTP PCSK9 LPL LCAT CETP APOE
3 Golgi apparatus GO:0005794 10.08 SAR1B PCSK9 MTTP APOE ANGPTL3 ABCG1
4 cell surface GO:0009986 10 SCARB1 PCSK9 LPL APOA1 ANGPTL3 ABCA1
5 endoplasmic reticulum lumen GO:0005788 9.95 PCSK9 MTTP APOE APOB APOA2 APOA1
6 early endosome GO:0005769 9.92 PCSK9 APOE APOC3 APOC2 APOB APOA2
7 low-density lipoprotein particle GO:0034362 9.71 APOE APOC2 APOB APOA1
8 chylomicron GO:0042627 9.7 LPL APOE APOC3 APOC2 APOB APOA2
9 endocytic vesicle lumen GO:0071682 9.67 APOE APOB APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.67 APOC3 APOC2 APOA2 APOA1
11 intermediate-density lipoprotein particle GO:0034363 9.65 APOE APOC3 APOC2 APOB APOA1
12 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
13 very-low-density lipoprotein particle GO:0034361 9.5 LPL APOE APOC3 APOC2 APOB APOA2
14 high-density lipoprotein particle GO:0034364 9.23 PLTP LCAT CETP APOE APOC2 APOB

Biological processes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 10.16 PCSK9 LCAT CETP APOE APOB APOA1
2 intermembrane lipid transfer GO:0120009 10.16 PLTP MTTP CETP APOE APOB APOA2
3 retinoid metabolic process GO:0001523 10.13 LPL APOE APOC3 APOC2 APOB APOA2
4 triglyceride homeostasis GO:0070328 10.13 SCARB1 MIR33A LPL CETP APOE APOC3
5 post-translational protein modification GO:0043687 10.11 PCSK9 APOE APOB APOA2 APOA1
6 triglyceride metabolic process GO:0006641 10.11 PCSK9 MTTP LPL CETP APOE APOC3
7 reverse cholesterol transport GO:0043691 10.1 SCARB1 LCAT CETP APOE APOC3 APOC2
8 chylomicron assembly GO:0034378 10.09 MTTP APOE APOC3 APOC2 APOB APOA2
9 phospholipid transport GO:0015914 10.08 SCARB1 PLTP MTTP CETP APOA1 ABCA1
10 low-density lipoprotein particle remodeling GO:0034374 10.08 MTTP LPA CETP APOE APOB APOA2
11 lipoprotein metabolic process GO:0042157 10.08 PCSK9 MTTP APOE APOC3 APOB APOA2
12 cellular protein metabolic process GO:0044267 10.07 PCSK9 APOE APOB APOA2 APOA1
13 chylomicron remodeling GO:0034371 10.07 LPL APOE APOC3 APOC2 APOB APOA2
14 high-density lipoprotein particle remodeling GO:0034375 10.07 SCARB1 PLTP LCAT CETP APOE APOC3
15 response to drug GO:0042493 10.06 LPL APOA1 ABCG5 ABCA1
16 phospholipid efflux GO:0033700 10.05 APOE APOC3 APOC2 APOA2 APOA1 ABCG1
17 phospholipid metabolic process GO:0006644 10.04 PCSK9 LPL LCAT APOA1 ANGPTL3
18 cholesterol transport GO:0030301 10.04 SCARB1 LCAT CETP APOB APOA2 APOA1
19 very-low-density lipoprotein particle remodeling GO:0034372 10.03 LPL LCAT CETP APOE APOC2 APOA1
20 receptor-mediated endocytosis GO:0006898 10.02 SCARB1 APOE APOB APOA1
21 cholesterol efflux GO:0033344 10.02 SCARB1 APOE APOC3 APOC2 APOB APOA2
22 phospholipid homeostasis GO:0055091 10 CETP APOA1 ANGPTL3 ABCG1 ABCA1
23 lipid transport GO:0006869 10 SCARB1 PLTP MTTP LPA CETP APOE
24 lipid catabolic process GO:0016042 9.99 LPL APOC3 APOC2 APOB
25 high-density lipoprotein particle clearance GO:0034384 9.99 SCARB1 APOE APOC2 APOA2 APOA1
26 lipoprotein biosynthetic process GO:0042158 9.97 LCAT APOE APOB APOA1 ABCA1
27 cholesterol metabolic process GO:0008203 9.96 PCSK9 LCAT CETP APOE APOB APOA2
28 positive regulation of cholesterol efflux GO:0010875 9.93 PLTP APOE APOA1 ABCA1
29 high-density lipoprotein particle assembly GO:0034380 9.93 APOE APOA2 APOA1 ABCA1
30 regulation of lipid metabolic process GO:0019216 9.92 APOA2 APOA1 ABCA1
31 response to nutrient GO:0007584 9.92 APOA1 ABCG5 ABCA1
32 chylomicron remnant clearance GO:0034382 9.92 APOE APOC3 APOC2 APOB
33 regulation of Cdc42 protein signal transduction GO:0032489 9.92 APOE APOC3 APOA1 ABCA1
34 lipid homeostasis GO:0055088 9.9 CETP APOE ANGPTL3
35 phosphatidylcholine biosynthetic process GO:0006656 9.86 LCAT APOA2 APOA1
36 triglyceride catabolic process GO:0019433 9.86 LPL APOC3 APOB
37 artery morphogenesis GO:0048844 9.85 APOE APOB ANGPTL3
38 low-density lipoprotein particle clearance GO:0034383 9.85 SCARB1 PCSK9 APOB
39 sterol transport GO:0015918 9.84 PLTP MTTP ABCG5
40 phosphatidylcholine metabolic process GO:0046470 9.84 LCAT CETP APOA1
41 very-low-density lipoprotein particle assembly GO:0034379 9.83 MTTP APOC3 APOB
42 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.83 CETP ABCG1 ABCA1
43 positive regulation of cholesterol esterification GO:0010873 9.83 APOE APOA2 APOA1
44 positive regulation of cholesterol storage GO:0010886 9.82 SCARB1 LPL APOB
45 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.82 APOC3 APOA2 APOA1
46 lipid metabolic process GO:0006629 9.8 PLTP PCSK9 MTTP LPL LPA LCAT
47 phospholipid catabolic process GO:0009395 9.76 APOA2 ANGPTL3
48 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.76 LPL APOB
49 negative regulation of lipid catabolic process GO:0050995 9.76 APOC3 APOA2
50 positive regulation of lipid biosynthetic process GO:0046889 9.76 APOE APOA1

Molecular functions related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10.05 LPL APOE APOA2 APOA1 ANGPTL3 ABCA1
2 heparin binding GO:0008201 9.95 LPL LPA APOE APOB ANGPTL3
3 phospholipid binding GO:0005543 9.93 APOE APOC3 APOB APOA2 APOA1 ABCG1
4 lipid binding GO:0008289 9.91 SCARB1 PLTP MTTP CETP APOE APOC3
5 phosphatidylcholine binding GO:0031210 9.83 PLTP CETP APOA2 APOA1 ABCA1
6 amyloid-beta binding GO:0001540 9.81 SCARB1 APOE APOA1
7 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.8 ABCG5 ABCG1 ABCA1
8 cholesterol binding GO:0015485 9.8 CETP APOC3 APOA2 APOA1 ABCG1 ABCA1
9 high-density lipoprotein particle binding GO:0008035 9.77 SCARB1 PLTP APOA2 APOA1 ABCA1
10 low-density lipoprotein particle receptor binding GO:0050750 9.76 PCSK9 APOE APOB
11 low-density lipoprotein particle binding GO:0030169 9.74 SCARB1 PLTP PCSK9
12 phospholipid transporter activity GO:0005548 9.73 MTTP CETP ABCA1
13 lipoprotein particle binding GO:0071813 9.71 LPL APOE APOA1
14 lipase inhibitor activity GO:0055102 9.71 APOC3 APOC2 APOA2 APOA1
15 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.7 APOE APOA2 APOA1
16 apolipoprotein A-I binding GO:0034186 9.69 SCARB1 LCAT ABCA1
17 high-density lipoprotein particle receptor binding GO:0070653 9.67 APOC3 APOA2 APOA1
18 apolipoprotein receptor binding GO:0034190 9.65 PCSK9 APOA2 APOA1
19 heparan sulfate proteoglycan binding GO:0043395 9.64 LPL APOE
20 intermembrane phosphotidylcholine transfer activity GO:0120019 9.63 PLTP MTTP
21 lipid transporter activity GO:0005319 9.63 MTTP APOE APOB APOA2 APOA1 ABCA1
22 phosphatidylcholine-translocating ATPase activity GO:0090554 9.62 ABCG1 ABCA1
23 very-low-density lipoprotein particle receptor binding GO:0070326 9.62 PCSK9 APOE
24 very-low-density lipoprotein particle binding GO:0034189 9.61 PLTP PCSK9
25 triglyceride binding GO:0017129 9.61 LPL CETP
26 phosphatidylethanolamine transporter activity GO:1904121 9.6 PLTP MTTP
27 intermembrane phospholipid transfer activity GO:0120014 9.59 PLTP MTTP
28 apolipoprotein binding GO:0034185 9.43 SCARB1 PCSK9 MTTP LPL LPA ABCA1
29 intermembrane cholesterol transfer activity GO:0120020 9.32 PLTP MTTP CETP APOE APOB APOA2
Sources

Sources for Hypolipoproteinemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....